This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
Chronic Weight Management
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
-
Ascletis Clinical Site, Rogers, Arkansas, United States, 72758
Ascletis Clinical Site, Fort Myers, Florida, United States, 33912
Ascletis Clinical Site, Miami, Florida, United States, 33172
Ascletis Clinical Site, Columbus, Ohio, United States, 43212
Ascletis Clinical Site, Bellaire, Texas, United States, 77401
Ascletis Clinical Site, San Antonio, Texas, United States, 78240
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
Ascletis Pharma (China) Co., Limited,
2026-01